8029 Background: Superiority of irinotecan over etoposide in combination with cis-or
carboplatin was demonstrated in a Japanese and a Scandinavian phase III trial. However …

An alternating regimen for the treatment of extensive-disease small-cell lung cancer (SCLC)
was compared with standard treatment with cyclophosphamide, doxorubicin, and vincristine …

A prospective randomised study was undertaken in patients with limited disease small cell
carcinoma of the lung (SCCL), which compared doxorubicin, 50 mg/m2, and vincristine, 2 …

PURPOSE: The combination of irinotecan and cisplatin (IP) has shown at least comparable
efficacy to that of etoposide/cisplatin (EP) in patients with extensive-stage small cell lung …

The current study reports the results of Adriamycin (doxorubicin), etoposide, and
cyclophosphamide (AVE) in small cell bronchogenic carcinoma. The overall rate of …

Abstract From January 1978 to March 1984, a series of 159 patients with newly diagnosed
small cell lung cancer (SCLC) was treated with combination chemotherapy with or without …

Purpose The efficacy of cisplatin, irinotecan, and bevacizumab was evaluated in patients
with extensive-stage small-cell lung cancer (ES-SCLC). Patients and Methods Patients with …

PURPOSE The primary objective of this randomized prospective study was to compare the
survival of limited-stage small-cell lung cancer (SCLC) patients treated with chemotherapy …

Seventy patients with limited-stage small-cell lung cancer (SCLC) were given six courses of
chemotherapy alternating two drug combinations: a combination of cyclophosphamide …

After stratification for extent of small cell lung cancer, 109 patients were randomized to
receive cycles of chemotherapy with cyclophosphamide, doxorubicin, and VP-16-213 …